TY - JOUR
T1 - A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa ( PACT‐MEA ): Study design and rationale
AU - Verma, Subodh
AU - Sabbour, Hani
AU - Alamuddin, Naji
AU - Alawadi, Fatheya
AU - Alkandari, Hessa
AU - Almahmeed, Wael
AU - Assaad‐Khalil, Samir H.
AU - Haddad, Jihad
AU - Lombard, Landman
AU - Malik, Rayaz A.
AU - Mashaki Ceyhan, Emel
AU - Prasad, Preethy
AU - Tombak, Gamze
AU - Salek, Sam
N1 - © 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-Non Commercial-No Derivs License. https://creativecommons.org/licenses/by-nc-nd/4.0/
PY - 2023/3/3
Y1 - 2023/3/3
N2 - Aim: To investigate the epidemiology and clinical management of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (eASCVD) or high/very high ASCVD risk, defined by the 2021 European Society of Cardiology Guidelines, in seven countries in the Middle East and Africa (PACT‐MEA; NCT05317845), and to assess physicians' attitudes and the basis for their decision‐making in the management of these patients. Materials and Methods: PACT‐MEA is a cross‐sectional, observational study undertaken in Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa and the United Arab Emirates based on a medical chart review of approximately 3700 patients with T2D in primary and secondary care settings, and a survey of approximately 400 physicians treating patients with T2D. Results: The primary and secondary objectives are to determine the prevalence of eASCVD and high/very high ASCVD risk in patients with T2D. Current treatment with cardioprotective antidiabetic medication, the proportion of patients meeting the treatment criteria for reimbursement in the study countries where there is an applicable reimbursement guideline, and physician‐reported factors in clinical decision‐making in T2D management, will also be assessed. Conclusions: This large cross‐sectional study will establish the estimated prevalence and management of eASCVD and high/very high ASCVD risk in patients with type 2 diabetes across the Middle East and Africa.
AB - Aim: To investigate the epidemiology and clinical management of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (eASCVD) or high/very high ASCVD risk, defined by the 2021 European Society of Cardiology Guidelines, in seven countries in the Middle East and Africa (PACT‐MEA; NCT05317845), and to assess physicians' attitudes and the basis for their decision‐making in the management of these patients. Materials and Methods: PACT‐MEA is a cross‐sectional, observational study undertaken in Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa and the United Arab Emirates based on a medical chart review of approximately 3700 patients with T2D in primary and secondary care settings, and a survey of approximately 400 physicians treating patients with T2D. Results: The primary and secondary objectives are to determine the prevalence of eASCVD and high/very high ASCVD risk in patients with T2D. Current treatment with cardioprotective antidiabetic medication, the proportion of patients meeting the treatment criteria for reimbursement in the study countries where there is an applicable reimbursement guideline, and physician‐reported factors in clinical decision‐making in T2D management, will also be assessed. Conclusions: This large cross‐sectional study will establish the estimated prevalence and management of eASCVD and high/very high ASCVD risk in patients with type 2 diabetes across the Middle East and Africa.
KW - CLINICAL STUDY DESIGN
KW - Africa
KW - atherosclerosis
KW - cardiovascular diseases
KW - diabetes complications
KW - epidemiology
KW - Middle East
KW - prevalence
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85150240301&partnerID=8YFLogxK
U2 - 10.1111/dom.15011
DO - 10.1111/dom.15011
M3 - Article
SN - 1462-8902
VL - 25
SP - 1444
EP - 1452
JO - Diabetes, Obesity and Metabolism (DOM)
JF - Diabetes, Obesity and Metabolism (DOM)
IS - 6
ER -